Pacira BioSciences, Inc. Common Stock (PCRX) is a publicly traded Healthcare sector company. As of September 16, 2026, PCRX trades at $24.90 with a market cap of $959.87M and a P/E ratio of 70.66. PCRX moved +3.34% today. Year to date, PCRX is -3.75%; over the trailing twelve months it is -6.04%. Its 52-week range spans $18.80 to $27.66. Analyst consensus is moderatebuy with an average price target of $28.67. Rallies surfaces PCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PCRX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $24.90 |
| Market Cap | $959.87M |
| P/E Ratio | 70.66 |
| EPS | $0.35 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.66 |
| 52-Week Low | $18.80 |
| Volume | 476.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $746.16M |
| Net Income | $14.64M |
| Gross Margin | 79.21% |
7 analysts cover PCRX: 0 strong buy, 3 buy, 3 hold, 1 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $28.67.